Amenamevir for treating acyclovir-resistant or refractory herpes simplex virus infection in allogeneic hematopoietic stem cell transplantation recipients: Two case reports
-
Published:2024-06
Issue:6
Volume:63
Page:107169
-
ISSN:0924-8579
-
Container-title:International Journal of Antimicrobial Agents
-
language:en
-
Short-container-title:International Journal of Antimicrobial Agents
Author:
Sallée LéoORCID,
Souchet Laetitia,
Boutolleau David,
Nguyen Stéphanie
Reference5 articles.
1. Surveillance of herpes simplex virus resistance to antivirals: a 4-year survey;Burrel;Antiviral Res,2013
2. Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant—a retrospective study;Ariza-Heredia;Transpl Int,2018
3. A phase 3, randomized, double-blind, placebo-controlled study evaluating a single, patient-initiated dose of amenamevir for recurrent herpes labialis;Kawashima;J Dermatol,2023
4. Single-dose, patient-initiated amenamevir therapy for recurrent genital herpes: a phase 3, randomized, double-blind, placebo-controlled study;Kawashima;Open Forum Infect Dis,2022
5. Herpes simplex virus helicase-primase inhibitors: recent findings from the study of drug resistance mutations;Biswas;Antivir Chem Chemother,2008
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献